Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) is discovering and developing new antibody immunotherapies that help the immune system attack diseased cells. The company relies on a unique ability to extensively interrogate the human immune microenvironment for candidate selection and validation in order to measure drug effects in a patient-specific manner. The company is building a pipeline of immunomodulators for the treatment of cancer and inflammatory diseases. For more information, visit the company’s website at www.enumeral.com.

Noble Financial Capital Markets, an equity research driven, full-service, investment banking boutique, is hosting its tenth annual equity conference in Sandpiper Bay, FL. Attended by institutional investors from across North America, the event features more than 140 public company executive teams from a diverse range of industries. For more information, visitwww.noble.missionir.com.